Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
495
Recruiting Now
495
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT07218146 Phase 3
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With ...
Condition
Small-cell Lung Cancer
Enrollment
480 pts
Location
United States, China, Japan
Sponsor
Zai Lab (Shanghai) Co., Ltd.
NCT03480568 Phase 3
Recruiting
Alirocumab in Patients on a Stable Dialysis Regimen
Condition
Hemodialysis
Enrollment
20 pts
Location
United States
Sponsor
Baylor Research Institute
NCT06825182 Phase 3
Recruiting
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Enrollment
1,000 pts
Location
China
Sponsor
Nanjing First Hospital, Nanjin
NCT07195591 Phase 3
Recruiting
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard o...
Condition
Glioblastoma
Enrollment
766 pts
Location
United States
Sponsor
GT Medical Technologies, Inc.
NCT07467213 Phase 3
Recruiting
Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastroi...
Condition
Acute Myocardial Infarction (AMI)
Enrollment
5,000 pts
Location
South Korea
Sponsor
Samsung Medical Center
NCT06319846 Phase 3
Recruiting
Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non...
Condition
Ischemic Stroke, Acute
Enrollment
4,674 pts
Location
China
Sponsor
Beijing Tiantan Hospital
NCT06952803 Phase 3
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standar...
Condition
Prostate Cancer
Enrollment
700 pts
Location
United States, Argentina, Australia
Sponsor
AstraZeneca
NCT05997979 Phase 3
Recruiting
Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children
Condition
Neuropathic Pain
Enrollment
46 pts
Location
France
Sponsor
University Hospital, Brest
NCT06498479 Phase 3
Recruiting
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cel...
Condition
Small Cell Lung Cancer
Enrollment
460 pts
Location
China
Sponsor
Hansoh BioMedical R&D Company
NCT06438627 Phase 3
Recruiting
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Ri...
Condition
Nasopharyngeal Carcinoma
Enrollment
164 pts
Location
China
Sponsor
XIANG YANQUN
NCT05333523 Phase 3
Recruiting
Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in L...
Condition
Laryngeal Squamous Cell Carcinoma
Enrollment
242 pts
Location
Netherlands
Sponsor
Radboud University Medical Cen
NCT07422480 Phase 3
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With ...
Condition
Myelodysplastic Syndrome
Enrollment
300 pts
Location
United States, Argentina, Australia
Sponsor
Takeda
NCT05456503 Phase 3
Recruiting
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-262...
Condition
Frontotemporal Lobar Degeneration
Enrollment
72 pts
Location
United States
Sponsor
University of Pennsylvania
NCT07193459 Phase 3
Recruiting
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes
Enrollment
360 pts
Location
China
Sponsor
Hangzhou Zhongmei Huadong Phar
NCT06710080 Phase 3
Recruiting
Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia
Condition
Inflammation
Enrollment
168 pts
Location
Canada
Sponsor
Ottawa Heart Institute Researc
NCT06172205 Phase 3
Recruiting
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizuma...
Condition
BCLC Stage C Hepatocellular Carcinoma
Enrollment
262 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital
NCT05703672 Phase 3
Recruiting
Switching to E-cigarettes in Smokers Not Interested in Quitting
Condition
Smoking Reduction
Enrollment
500 pts
Location
United States
Sponsor
University of Kansas Medical C
NCT06648772 Phase 3
Recruiting
Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis:...
Condition
Plaque Psoriasis
Enrollment
189 pts
Location
China
Sponsor
Hangzhou Zhongmei Huadong Phar
NCT06162286 Phase 3
Recruiting
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety an...
Condition
Community-acquired Bacterial Pneumonia
Enrollment
100 pts
Location
China
Sponsor
Zai Lab (Hong Kong), Ltd.
NCT07067866 Phase 3
Recruiting
Weaning Approaches for Vasopressin in Sepsis
Condition
Septic Shock
Enrollment
82 pts
Location
Brazil
Sponsor
Hospital Nossa Senhora da Conc
NCT07186803 Phase 3
Recruiting
AI and Safety in Laparoscopic Cholecystectomy: A Randomized Controlled Trial
Condition
Laparoscopic Cholecystectomy
Enrollment
70 pts
Location
Canada
Sponsor
University Health Network, Tor
NCT03961373 Phase 3
Recruiting
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy f...
Condition
Locally Advanced Gastric Cancer
Enrollment
539 pts
Location
Italy
Sponsor
University of Siena
NCT07006675 Phase 3
Recruiting
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Frac...
Condition
Tibial Fractures
Enrollment
1,000 pts
Location
United States, Canada
Sponsor
Major Extremity Trauma Researc
NCT06380751 Phase 3
Recruiting
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocr...
Condition
Advanced Breast Cancer
Enrollment
500 pts
Location
United States, Argentina, Australia
Sponsor
AstraZeneca
NCT06853951 Phase 3
Recruiting
Cardioprotection on Chemotherapy-Induced Cardiotoxicity
Condition
Cardiotoxicity
Enrollment
30 pts
Location
Egypt
Sponsor
Ain Shams University
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology